[8-K] Aclaris Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

On 30 June 2025, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed an 8-K solely to furnish an updated corporate overview presentation (Exhibit 99.1) under Item 7.01 – Regulation FD Disclosure. The deck has been posted to the company’s website and is not deemed “filed” for Exchange Act liability or for incorporation by reference. No financial results, strategic transactions, or operational updates were disclosed. All other sections, including Item 9.01, merely list the exhibit numbers, and the filing was signed by CFO Kevin Balthaser.

Insights

Financial Analyst

TL;DR: Routine Reg FD filing; no new financials or guidance, low market impact.

This 8-K only furnishes an updated investor presentation. Because the submission is under Item 7.01, the information is expressly non-filed and carries no accounting implications. There are no revenue figures, pipeline updates, or strategic announcements, so valuation models remain unchanged. Investors may review the slide deck for cosmetic updates, but material catalysts are absent, rendering the disclosure neutral.

Corporate Governance Expert

TL;DR: Standard disclosure demonstrates compliance with Reg FD; governance stance unchanged.

Management continues to observe best practices by publicly releasing its investor materials. The choice to keep the presentation as “furnished” limits potential liability and signals the content is informational rather than decisive. No board or executive changes, litigation, or risk factors were noted. Accordingly, the governance risk profile is unaffected and the filing should not influence shareholder voting or stewardship considerations.

0001557746false00015577462025-06-302025-06-30

​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549​

​FORM 8-K​CURRENT REPORTPursuant to Section 13 or 15(d) ofThe Securities Exchange Act of 1934​Date of Report (Date of earliest event reported): June 30, 2025​

​Aclaris Therapeutics, Inc.(Exact name of registrant as specified in its charter)​

​	​	​	​	​
Delaware	​	001-37581	​	46-0571712
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​701 Lee Road, Suite 103Wayne, PA 19087(Address of principal executive offices, including zip code)​(484) 324-7933(Registrant’s telephone number, including area code)​N/A(Former name or former address, if changed since last report)​Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))​Securities registered pursuant to Section 12(b) of the Act: ​

Title of Each Class:		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock, $0.00001 par value		ACRS		The Nasdaq Stock Market, LLC

​Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).​Emerging growth company ☐​If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐​

​

Item 7.01 Regulation FD Disclosure.​On June 30, 2025, Aclaris Therapeutics, Inc. (the “Registrant”) updated its corporate overview presentation, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The updated corporate overview presentation is also available on the Registrant’s website.​In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.​Item 9.01 Financial Statements and Exhibits.​(d) Exhibits

Exhibit
Number		Exhibit Description
99.1	​	Company Presentation.
104		The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on June 30, 2025, formatted in Inline XBRL.

​​​​​​​

2

SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.​

​	​	ACLARIS THERAPEUTICS, INC.
​	​	​
​	By:	/s/ Kevin Balthaser
Date: June 30, 2025	​	Kevin Balthaser
​	​	Chief Financial Officer

​​

3

FAQ

What did Aclaris Therapeutics (ACRS) disclose in its June 30 2025 Form 8-K?

The company furnished an updated corporate overview presentation (Exhibit 99.1) under Item 7.01.

Does the June 30 2025 8-K include new financial results for ACRS?

No. The filing contains no financial statements, earnings data, or guidance.

Is the information in Exhibit 99.1 considered "filed" with the SEC?

No. Under General Instruction B.2 the information is "furnished," not "filed," limiting Exchange Act liability.

Where can investors find Aclaris Therapeutics’ updated presentation?

The slide deck is available as Exhibit 99.1 to the 8-K and on the company’s website.

Did Aclaris announce any mergers, acquisitions, or partnerships in this filing?

No. The 8-K does not mention any major transactions.

Who signed the June 30 2025 Form 8-K for Aclaris Therapeutics?

Chief Financial Officer Kevin Balthaser signed the report.